PROVEN-Dia: Brazilian Diabetes Prevention Program: Pilot Study

Sponsor
Beneficência Portuguesa de São Paulo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05689658
Collaborator
(none)
220
2
8.5

Study Details

Study Description

Brief Summary

To structure a Brazilian Diabetes Prevention Program based on guidance for changing lifestyle promoted by the American Diabetes Prevention Program, using materials already developed by the Brazilian Ministry of Health and contextualizing it to the Brazilian Public Health System (SUS) and evaluating its effectiveness in a multicentric randomized clinical trial with 220 pre-diabetic patients and a follow up of 3 months. Outcomes are diet quality and time of physical activity. Health care professionals' perceptions regarding its incorporation into clinical practice will also be evaluated.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Brazilian Diabetes Prevention Program
  • Behavioral: Diet
Phase 3

Detailed Description

This is a multicentric randomized clinical study coordinated by the Hospital Beneficência Portuguesa in São Paulo-Brazil and made possible by PROADI-SUS (SUS Institutional Development Support Program).

The study's objective is the Brazilian Diabetes Prevention Program development based on guidance for changing lifestyle promoted by the American Diabetes Prevention Program, using materials already developed by the Brazilian Ministry of Health and contextualizing it to the Brazilian Public Health System (SUS).

The program will not include a multidisciplinary orientation, but the prescription will have a multi-professional vision. The objective is to bring the multi-team together to discuss different aspects of the same intervention, such as accessibility, motivation, contexts, and needs, so that the program, to be guided by the nutritionist, can also be recognized and supported by the other teammates.

Once the program is defined, the research teams from the collaborating centers will be trained and qualified. 220 individuals with pre-diabetes will be included in the study and followed for 3 months. Outcomes are diet quality and time of physical activity. Health care professionals' perceptions regarding its incorporation into clinical practice will also be evaluated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
220 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Brazilian Diabetes Prevention Program: Pilot Study
Anticipated Study Start Date :
Mar 15, 2023
Anticipated Primary Completion Date :
Jul 15, 2023
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Brazilian Diabetes Prevention Program Group

The program will be based on the American Diabetes Prevention Program (DPP), whose published results are used as a reference for prediabetic care patients in the Brazilian Diabetes Guideline. In order to reach the weight loss goal estimated at 0.5 to 1 Kg per week and 150 minutes of moderate physical activity per week, the program will offer individual and group visits, qualitative guidelines for improving diet, lifestyle and self-care.

Behavioral: Brazilian Diabetes Prevention Program
A Program structured in 7 visits (in group and individual) to guide the improvement of diet quality, self-care, and practice of physical activity

Active Comparator: Diet Group

Diet prescription for weight loss

Behavioral: Diet
Hypocaloric diet prescription

Outcome Measures

Primary Outcome Measures

  1. Quality of diet [3 months]

    to compare mean score of Brazilian Cardioprotective Nutritional Program dietary index (BALANCE DI) between groups. the index has a score from 0 to 40, with a high score indicating adherence to a healthy diet (BALANCE).

  2. Minutes of Moderate Physical activity [3 months]

    to compare mean time in minutes of practice of moderate/vigorous physical activity over a week between groups

Secondary Outcome Measures

  1. Implementation Barriers and Facilitators [3 months]

    Identification of Barriers and Facilitators of Program implementation from a qualitative analysis approach

  2. Moderate or vigorous physical activity (according to IPAQ-short) [3 months]

    to compare proportion of individuals who perform at the end of the follow-up moderate or vigorous physical activity

  3. Cardioprotective diet adherence [3 months]

    to compare adherence to a healthy and cardioprotective diet based on the Cardiovascular Health Diet Index (CHDI) between groups. The CHDI had 11 components and a total score ranging from 0 to 110 points. the higher the score, the greater adherence to a healthy and cardioprotective diet

  4. Global DNA Methylation [Baseline]

    participants' global DNA methylation using the RRBS method (Reduced Representation Bisulfite Sequencing).

  5. weight [3 months]

    to compare mean weight (kg) between groups

  6. HbA1c [3 months]

    to compare mean HbA1c(%) between groups

  7. Glycemia [3 months]

    to compare mean Glycemia (mg/dL) between groups

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Body mass index greater than or equal to 24kg/m2

  • Have one of the following criteria: (CDC criteria for participating in the DPP)

  1. Diagnosis of prediabetes or

  2. Fasting blood glucose between 100-125mg/dl or blood glucose 2h after oral glucose tolerance test between 140 and 199mg/dl or HbA1c between 5.7 and 6.4% (maximum test date: last 3 months) or

  3. Previously diagnosed with gestational diabetes or

  4. High risk on the CDC prediabetes risk test

  • With Internet access

  • With personal cell phone access

  • No prior nutritional monitoring (6 months)

  • Live at least 60 minutes from the survey call center

Exclusion Criteria:
  • Diagnosis of Diabetes Mellitus

  • In secondary prevention for cardiovascular disease

  • HIV patient with detectable viral load (amount of virus greater than 40 copies per ml of blood)

  • Presence of illnesses that could seriously reduce your life expectancy or your ability to participate in the study

  • Refuse to participate in the study (signing the Free and Informed Consent Form)

  • Participation in another Randomized Clinical Trial whose objective interferes with the primary outcome of this research, such as diet quality and physical activity level

  • Pregnant and lactating women

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Beneficência Portuguesa de São Paulo

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beneficência Portuguesa de São Paulo
ClinicalTrials.gov Identifier:
NCT05689658
Other Study ID Numbers:
  • PROVEN-Dia
First Posted:
Jan 19, 2023
Last Update Posted:
Jan 19, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 19, 2023